# MarketVIEW: Zika vaccines (CAT: VAMV068)

| | | |
|---|---|---|
| **Product Name** | : | **MarketVIEW:** Zika vaccines |
| **Description** | : | Global vaccine commercial opportunity assessment |
| **Contents** | : | Executive presentation (~150 slides .pdf) + MS-forecast model(s) (.xls) |
| **Therapeutic Area** | : | **Endemic/travel vaccines** |
| **Publication date** | : | April 2023 |
| **Catalogue No** | : | VAMV068 |

## Background

**Zika virus (ZIKV)** is a member of the *flaviviridae* family that includes several mosquito-borne viruses of major clinical importance, including yellow fever virus, Japanese encephalitis virus and dengue virus. Although widely distributed across West and East Africa and Southeast Asia (89 countries/territories as of 2021), ZIKV has only recently been identified as a major cause of severe disease. The WHO declared the Zika virus outbreak a global emergency in February 2016. In most cases, ZIKV usually causes a mild and often asymptomatic illness. However, **neonatal microcephaly syndrome (SCZ)** and **Guillain-Barre syndrome (GBS)** are now established as severe complications of ZIKV infection. For example, in Brazil, an estimated 200,000 ZIKV (probable + confirmed) cases have persisted since 2017 (after the 2015/16 peak). 3,707 neonatal microcephaly confirmed cases have been reported although many are under-investigation (Ministeria de Saude, Brazil).

**ZIKV** has the potential to spread to other countries in the PAHO region/ROW that have *Aedes* mosquitoes. Autochthonous ZIKV transmission (albeit rare) has occurred in the US where the Gulf coast region and Florida are most vulnerable regions. Similarly, in the EU, autochthonous has occured in the Var department in France, 2019. Many private sector companies and government-funded organizations are working on developing a Zika vaccine due to the significant global public health concern. Key companies are **ModernaTX (mRNA-1893)**, **Takeda Vaccines (TAK-426)** and **Valneva SE (VLA1601)**.

This **MarketVIEW** product is a comprehensive MS Excel-based model + Executive presentation that forecast the potential commercial value of Zika virus vaccines across endemic (public + private), stockpile and travelers markets to 2035. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates for all key commercial segments. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up-to-date review is also given for latest disease background and epidemiology, with current R&D status.

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom  **Tel.** +44(0)1279 927049  **e-mail:** info@vaczine-analytics.com

# Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Zika vaccines in each respective market. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised including Chikungunya, dengue and JEV pathogens

## PRODUCT CONTENTS:

**Published April 2023 (CAT No: VAMV068)**
****This product is a summary presentation (.pdf), an MS-workbook (.xls)

**Contents – Summary presentation (.pdf)**
Contents
Author's notes
**Executive summary**
**[SECTION 1]** ZIKA vaccines: commercial model key outputs
**[SECTION 2]** ZIKA: disease background and epidemiology
**[SECTION 3]** ZIKA: pathogenesis, diagnosis, clinical features, management and prevention
**[SECTION 4]** ZIKA vaccines: R&D pipeline/competitor activity
**[SECTION 5]** ZIKA vaccines: modelling commercial potential
**[SECTION 6]** ZIKA vaccines: source material, previous 2017 analysis
References/bibliography
About **VacZine Analytics**
Disclaimer

**PAGES: >150 slides fully referenced/sourced. Available in .pdf form**

**Contents – MS-Excel workbook (.xls)**

Brazil (public + private sector), 3
target cohorts for each country
Mexico
Colombia
Venezuela
Peru
El Salvador
Guatemala
Bolivia
Belize
PAHO - Higher income
PAHO - Lower income
Paraguay
Peru
Venezuela
India
Indonesia
Philippines
Singapore
Malaysia
Thailand

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   Tel. +44(0)1279 927049   e-mail: info@vaczine-analytics.com

**PRODUCT COST:**
**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- o FULL PRODUCT - USD **$8,995**/ GBP **£7,375**[#] (Single region license only)*

*Single region = North America or Europe or ROW (non-exclusive, non-transferable license)
For orders in the UK, VAT at 20% will be added to final invoice total
*# - indicative prevailing rate will be applied on date of transaction*

**HOW TO ORDER:**
To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics ®** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
**VacZine Analytics ®** and the **"spiral logo"** are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...          www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom  **Tel.** +44(0)1279 927049  **e-mail:** info@vaczine-analytics.com

**BIBLIOGRAPHY**

➢ 150 References – available upon request

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   Tel. +44(0)1279 927049   e-mail: info@vaczine-analytics.com

## TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as "The Company"). (Herein [enter client name] to as "The Client").

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).

2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.

3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.

4. If not purchased online invoices are payable within **thirty days** of the invoice date.

5. All proposals are quoted in **$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.

6. The Company agrees not to disclose to any third-party confidential information acquired while providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**
A division of Assay Advantage Ltd
Warren (Carlton) House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049
E-mail: info@vacZine-analytics.com

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   Tel. +44(0)1279 927049   e-mail: info@vaczine-analytics.com

# About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

**VacZine Analytics ®** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
**VacZine Analytics ®** and "the spiral logo" are UK Registered Trademarks, 2009

*Since 2007*

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   **Tel.** +44(0)1279 927049   **e-mail:** info@vaczine-analytics.com

Bringing life to vaccine strategy...

**www.vaczine-analytics.com**

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44(0)1279 927049 **e-mail: info@vaczine-analytics.com**